Coronavirus

In the video series "Ask the Expert", experts from ETH Zurich answer questions from the community. In this episode Klaus Eyer talks about vaccinations.

SARS-CoV-2 is critically dependent on a special mechanism for the production of its proteins. A collaborative team led by a research group at ETH Zurich obtained molecular insights into this process and demonstrated that it can be inhibited by chemical compounds, thereby significantly reducing viral replication in infected cells.

A study published today in Nature shows that the NHS COVID-19 app for digital contact tracing, based on the DP3T protocol, averted between 300,000 and 600,000 COVID-19 cases in England and Wales. The researchers used data from the NHS to show and quantify the epidemiological impact of such privacy-preserving apps, which are now available around the globe to help control the pandemic.

Researchers at Goethe University Frankfurt, in cooperation with PSI, have probably discovered another, previously unknown mechanism of action of the antiviral remdesivir. Using structural analyses, they have discovered that a decomposition product of the virostatic agent remdesivir binds to the viral protein nsP3 of Sars-CoV-2. This protein helps the virus suppress host cell defence mechanisms. The discovery may be important for the development of new drugs to combat Sars-CoV-2 and other RNA viruses.

Since February 2021, the canton of Grisons is using saliva-based PCR mass testing within its mobile workforce as a potential means to contain the COVID-19 pandemic and reduce infection rates. Empa researchers are now leading the analysis of data from the first eight weeks of the testing regime. They observed a reduction in the incidence rate between 20 and 50%, depending on the business sector, and a noticeable reduction in the test positivity rate among those who were regularly tested. This suggests that viral propagation can indeed be contained through regular mass testing.